Barnidipine HCl (Mepirodipine; Y 198561; YM-730; YM09730-5) is a novel and potent calcium channel blocker with antihypertensive effects. As an L-type calcium antagonist (CaA), it has high affinity for [3H] initrendipine binding sites (Ki=0.21 nmol/l), and exhibits selective action against CaA receptors. Barnidipine hydrochloride (Mepirodipine hydrochloride) is an antihypertensive drug and acts by the reduction of peripheral vascular resistance secondary to its vasodilatory action.
Physicochemical Properties
| Molecular Formula | C27H30CLN3O6 |
| Molecular Weight | 528.0 |
| Exact Mass | 527.182 |
| Elemental Analysis | C, 61.42; H, 5.73; Cl, 6.71; N, 7.96; O, 18.18 |
| CAS # | 104757-53-1 |
| Related CAS # | Barnidipine;104713-75-9;Barnidipine-d5 hydrochloride |
| PubChem CID | 443868 |
| Appearance | Light yellow to yellow solid powder |
| Boiling Point | 614.5ºC at 760 mmHg |
| Melting Point | 223-226°C |
| Flash Point | 325.4ºC |
| Vapour Pressure | 4.94E-15mmHg at 25°C |
| LogP | 5.412 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 37 |
| Complexity | 917 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)O[C@@H]3CN(CC4=CC=CC=C4)CC3.[H]Cl |
| InChi Key | XEMPUKIZUCIZEY-YSCHMLPRSA-N |
| InChi Code | InChI=1S/C27H29N3O6.ClH/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H31H/t22-,25-/m0./s1 |
| Chemical Name | 3-((S)-1-benzylpyrrolidin-3-yl) 5-methyl (S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride |
| Synonyms | Mepirodipine HClY198561 YM 09730 YM730Y-198561 YM-09730 YM-730Y 198561 YM09730-5 YM09730 YM 730 Barnidipine Hydrochloride Barnidipine HCl |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Pharmacological profile of barnidipine: a single optical isomer dihydropyridine calcium antagonist. Blood Press Suppl. 1998;1:5-8. [2]. Barnidipine. Drugs. 2001;61(7):989-96; discussion 997-8. |
| Additional Infomation | Barnidipine hydrochloride is a dihydropyridine. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~473.48 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8939 mL | 9.4697 mL | 18.9394 mL | |
| 5 mM | 0.3788 mL | 1.8939 mL | 3.7879 mL | |
| 10 mM | 0.1894 mL | 0.9470 mL | 1.8939 mL |